EGFR and non-small cell lung carcinoma: For example in NSCLC, MET amplification drives resistance to the EGFR inhibitor gefitinib; whereas in ALK-positive NSCLC, ALK inhibition can be overcome by EGFR or KIT activation [23, 41].